25D-NBOMe
25D-NBOMe is the N-(2-methoxybenzyl) derivative of 2C-D, a potent 5-HT2A agonist psychedelic active in the sub-milligram range. Like the rest of the NBOMe family it is orally inactive, taken sublingually, and shares the series' narrow safety margin and vasoconstrictive, seizure-prone toxicity profile.
01 Overview
25D-NBOMe emerged as part of the wave of 25x-NBOMe blotter research chemicals sold from around 2012. It is far less studied than 25I- or 25C-NBOMe and human information is essentially anecdotal.
As with all NBOMes, the microgram-to-low-milligram active range means blotter and volumetric dosing errors are dangerous. Reported acute effects mirror the class: stimulation, visuals, vasoconstriction, and at high doses agitation, hyperthermia and seizures.
02 Mechanism
Potent agonist at serotonin 5-HT2A receptors; the N-2-methoxybenzyl substitution on the 2C-D scaffold greatly increases 5-HT2A affinity and potency versus the parent phenethylamine.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 200–500 µg | Sublingual | Potency less well defined than 25I/25C; treat estimates cautiously. |
| Common | 500–1500 µg | Sublingual | Anecdotal ranges only. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Psychedelic visuals and cognition changeColour and geometric visuals with altered thought, comparable to other 25x-NBOMe compounds. | 6-10 h | Anecdotal | |
| StimulationBody load, restlessness and difficulty sleeping typical of the series. | moderate-marked | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| VasoconstrictionCold, painful extremities and hypertension consistent with peripheral 5-HT2A activation. | Severe | Common | Anecdotal | |
| Overstimulation and seizuresHigh doses can cause agitation, hyperthermia and seizures as with other NBOMes. | Life-threatening | Uncommon | Anecdotal |